NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SUNREST · data 2026-10-31
Sunrest Lifescience Limited
In plain words
Price: 27.3% below its 52-week high of ₹54.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹71 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | 43.4% |
| Profit growth, 3 years (yearly) | 26.3% |
At a glance
P/E 4.5, P/B 0.8, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 22.4%, ROCE 25.9%, operating margin 11.3%: how much profit it earns on the money it uses.
Debt/equity 0.85, Profit growth 26.3% and sales growth 43.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (22.4%).
- Profit grew 26.3% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Sunrest Lifescience Limited debt-free?
Its latest reported debt-to-equity ratio is 0.85.
What is Sunrest Lifescience Limited's P/E ratio?
About 4.5, based on the last 12 months' earnings and a price of ₹39.25 (data 2026-10-31).
What is the 52-week high and low of Sunrest Lifescience Limited?
The 52-week high is ₹54 and the 52-week low is ₹29.55.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sunrest Lifescience Limited | ₹39.25 | ₹17 cr | 4.5 | 0.8 | 22.4% | 25.9% | 0.85 | -6.5% |
| Mangalam Drugs & Organics Ltd. | ₹28.61 | ₹46 cr | — | — | -35.2% | -22.8% | 1.08 | -58.2% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
| Medi-Caps Ltd. | ₹24.69 | ₹30 cr | — | — | -2.6% | -9.5% | 0 | -5.8% |
| Lasa Supergenerics Ltd. | ₹4.67 | ₹25 cr | — | — | -51.1% | -27% | 0.2 | -55.1% |
| Ortin Global Ltd | ₹13.35 | ₹10 cr | — | — | -46.1% | -46.3% | 0.81 | +18.7% |
Compare SUNREST with MANGALAM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SUNREST in NSE Scanner →